FDA approval for Stealth BioTherapeutics' elamipretide has been a long time coming. What does this mean for other ultra-rare disease companies? The post First-ever approval for Barth Syndrome treatment: what does this mean for ultra-rare disease therapeutics? appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and l...
